Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Ophthalmology|July 9, 2014
Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edemaYi Zhang, Zhenling Yao, Nitin Kaila, et al.Ophthalmology|July 13, 2014
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationAllen C Ho, Brandon G Busbee, Carl D Regillo, et al.Ophthalmology|April 13, 2010
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III studyDavid M Brown, Peter A Campochiaro, Rishi P Singh, et al.Ophthalmology|January 8, 2014
Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trialsSophie J Bakri, Darius M Moshfeghi, Steve Francom, et al.Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.Journal of the American Academy of Dermatology|December 4, 2019
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, et al.Journal of the American Academy of Dermatology|October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE studyKim A Papp, Shahram Jacobs, Howard Sofen, et al.Clinical and Translational Science|November 28, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study designSibel Ucpinar, Joyce K Kwan, Joshua D Hoffman, et al.Ophthalmology|June 21, 2011
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III studyDavid M Brown, Peter A Campochiaro, Robert B Bhisitkul, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|June 15, 2017
Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and PlaceboJean Carruthers, Nowell Solish, Shannon Humphrey, et al.Pageof 4